Treatment reprogramming celiac white blood cells so that gluten proteins are not affected
Nov 7, 2018, 16h07
Sao Paulo – one vaccine which can allow people who have celiac disease to consume glutane safely entered the second stage of the test, when we have gone for more than a decade.
The results of the first phase of the test showed that Nexvax2, the name of the immune response, is safe and tolerable. The next step is to evaluate the efficacy of the vaccine in patients.
Nexvax2 reprograms T cells (or T lymphocytes, a group of white blood cells responsible for body protection) that do not interfere with some of the effects of amino acids – peptides – gluten-forming proteins, exposing three of these peptides to body-modified forms repeatedly.
An approximately 80% to 90% celiac inflammatory reaction to gluten, which causes the destruction of the intestinal tract, if it is commonly used, results from the fact that they have the HLA-DQ2.5 gene, which produces a recognized protein that causes T-cell gluten lipids to be labeled as dangerous, although in fact they are harmless.
"The launch of our second phase Nexvax2 trial is important for patients suffering from celiac disease, affecting about 1% of the world's population," said Leslie Williams, executive director of the Nexvax2 ImmusanT company. earlier this year. "This study was intended to demonstrate the protection against inactivated gluten, but the main objective is to develop Nexvax2 as a treatment that will allow patients to return to unlimited diets."
The vaccine is an unlimited dietary hope
To carry out the study, the team plans to register 150 celiac patients in the United States, Australia and New Zealand. Participants will receive 32 total Nexvax2 or placebo injections twice a week, and then face masked gluten (which means they do not know if the food contains glutin). The company reported that the first patient entered the test and started receiving injections at the end of September.
"Gluten-free diets are the only treatment for celiac disease, but it's cumbersome, complicated and not always effective. Even the most sophisticated patients may be adversely affected by adverse effects," explains Jason Tye-Din, a gastroenterologist and research coordinator.
According to the ImmusanT site, treatment with Nexvax2 involves multiple doses to gradually record T cells with gluten peptides. During this time, damage to the inflammatory and intestinal tract can be cured by relieving the symptoms of the disease. Researchers work with the possibility that an individual can consume small amounts of gluten or free of charge, without reference to the immune system.